WVE Key Statistics, Chart & Performance
The current stock price of WVE is 13.45 USD. In the past month the price decreased by -9.31%. In the past year, price increased by 20.41%.
WVE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to WVE. When comparing the yearly performance of all stocks, WVE is one of the better performing stocks in the market, outperforming 91.61% of all stocks.
WVE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to WVE. No worries on liquidiy or solvency for WVE as it has an excellent financial health rating, but there are worries on the profitability.
WVE Financial Highlights
Over the last trailing twelve months WVE reported a non-GAAP Earnings per Share(EPS) of -0.75. The EPS increased by 32.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.62% | ||
| ROE | -92.42% | ||
| Debt/Equity | 0 |
WVE Forecast & Estimates
20 analysts have analysed WVE and the average price target is 34.49 USD. This implies a price increase of 156.42% is expected in the next year compared to the current price of 13.45.
For the next year, analysts expect an EPS growth of -51.97% and a revenue growth -20.32% for WVE
WVE Ownership
WVE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.53 | 1T | ||
| JNJ | JOHNSON & JOHNSON | 20.6 | 578.208B | ||
| MRK | MERCK & CO. INC. | 22.54 | 302.633B | ||
| PFE | PFIZER INC | 9.06 | 154.765B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.19 | 126.196B | ||
| ZTS | ZOETIS INC | 18.55 | 56.153B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.61 | 25.774B | ||
| VTRS | VIATRIS INC | 5.76 | 16.793B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.1 | 12.521B | ||
| AXSM | AXSOME THERAPEUTICS INC | 222.91 | 9.202B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About WVE
Company Profile
Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. The company employs 287 full-time employees The company went IPO on 2015-11-11. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
Company Info
WAVE LIFE SCIENCES LTD
7 Straits View, #12-00, Marina One East Tower
Singapore 018936 SG
CEO: Paul B. Bolno
Employees: 287
Phone: 6562363388
WAVE LIFE SCIENCES LTD / WVE FAQ
What does WAVE LIFE SCIENCES LTD do?
Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. The company employs 287 full-time employees The company went IPO on 2015-11-11. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
What is the current price of WVE stock?
The current stock price of WVE is 13.45 USD. The price increased by 5.49% in the last trading session.
Does WAVE LIFE SCIENCES LTD pay dividends?
WVE does not pay a dividend.
What is the ChartMill technical and fundamental rating of WVE stock?
WVE has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is WAVE LIFE SCIENCES LTD (WVE) stock traded?
WVE stock is listed on the Nasdaq exchange.
How is the market expecting WVE stock to perform?
20 analysts have analysed WVE and the average price target is 34.49 USD. This implies a price increase of 156.42% is expected in the next year compared to the current price of 13.45.
What is the Short Interest ratio of WAVE LIFE SCIENCES LTD (WVE) stock?
The outstanding short interest for WAVE LIFE SCIENCES LTD (WVE) is 10.69% of its float.